REG - Ondine Biomedical - Seasoned MedTech Exec Appointed as CFO & COO

Ondine BiomedicalAnnouncement

26/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250226:nRSZ4437Ya&default-theme=true

RNS Number : 4437Y  Ondine Biomedical Inc.  26 February 2025

26 February 2025

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

 

Ondine Biomedical Strengthens Leadership Team with the Appointment of Michael
Behlke as non-Board CFO & COO

 

Ondine Biomedical Inc. (LON: OBI), a global leader in light-activated
antimicrobial treatments, is pleased to announce the appointment of Michael S.
Behlke as Chief Financial Officer (CFO) and Chief Operating Officer (COO),
effective immediately. Recognized in the US MedTech community for his career
achievements, Mr. Behlke brings over 30 years of financial and operational
leadership experience, positioning Ondine for accelerated growth and
commercialization success.

 

Mr. Behlke's distinguished career includes securing over $250 million in
funding, supporting acquisitions exceeding $700 million, and driving
commercialization strategies for emerging and mid-stage medical companies.
Prior to joining Ondine, he served as CFO and Acting COO at Ventec Life
Systems with full P&L responsibility, where he played a critical role in
scaling the company's revenue from $13 million to $500 million annually and in
its landmark partnership with General Motors to rapidly scale up and
manufacture ventilators for the US Strategic National Stockpile during the
COVID-19 pandemic.

 

Carolyn Cross, Ondine's Chief Executive Officer:

"We are thrilled to welcome Michael to our leadership team. Ondine is at a
critical inflection point as we expand our hospital-based infection prevention
solutions. Michael's extensive MedTech industry experience, operational
leadership, and business transformation successes will be key to accelerating
our worldwide commercialization efforts, initially within Canada and the
UK/EU, and then rapidly expanding into the U.S. post-FDA approval."

 

In his new role, Mr. Behlke will oversee Ondine's capital markets strategies,
operational efficiency, and international expansion, ensuring the company's is
well-positioned for sustained growth and market leadership. His deep expertise
in P&L management, business transformation, and supply chain execution
will be key to advancing Ondine's mission of revolutionizing infection
prevention through its photodisinfection-based platform technology.

 

Michael Behlke, CFO & COO of Ondine Biomedical:

"I am honored to join Ondine at this pivotal moment. The company's
groundbreaking photodisinfection technology represents a paradigm shift in
infection control. I look forward to working with this talented team to drive
operational excellence, financial growth, and global adoption of this
life-saving technology."

This appointment strengthens Ondine's leadership team and underscores the
Company's commitment to expanding its footprint in key global markets and
addressing the urgent need for innovative antimicrobial solutions in
healthcare settings.

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com (https://ondinebio.com/)
 Carolyn Cross, CEO                                          Via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 RBC Capital Markets (Broker)
 Rupert Walford, Kathryn Deegan                              +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                            +44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies (also known as 'photodisinfection') to
prevent and treat infections, including those caused by antibiotic-resistant
bacteria. Ondine's patented light-activated antimicrobial technology offers a
safe, rapid, and effective alternative to traditional antibiotics, tackling
some of the most pressing healthcare challenges today.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUVSWRVAUUUAR